Prilenia
http://www.prilenia.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Prilenia
Apellis Follows Wave Life By Shelving ALS Candidate After Trial Miss
Apellis’s pegcetacoplan – approved for two other indications – will not go forward in amyotrophic lateral sclerosis after a Phase II failure, two days after Wave Life made a similar call in the neurodegenerative disease.
Clene Confident In Phase III Plans For CNM-Au8 In ALS With Six-Month Data
The company announced detailed data for the drug in the HEALEY-ALS Platform Trial, where the cohort of the Phase II/III study testing it nevertheless failed to meet the primary endpoint.
Prilenia Plans To Continue With Pridopidine In ALS Despite Platform Study Miss
Pridopidine is the latest ALS drug candidate to miss the primary endpoint in the HEALEY-ALS platform study, but the S1R agonist did indicate potential benefits in speech and a key biomarker of the disease.
Biohaven’s Non-Migraine Portfolio Takes Another Hit As Verdiperstat Fails In ALS
Pfizer is buying Biohaven's migraine portfolio, but the rest of the pipeline is poised to be spun out and there have been two development setbacks. Despite verdiperstat's failure in ALS, the field had a same-day win with Amylyx's Relyvrio approval.
Company Information
- Industry
- Biotechnology
- Diversified
- Pharmaceuticals
-
Pharmaceuticals
- Chiral Chemistry
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Liposomes
- Nanotechnology, Chips, etc.
- Pharmacogenetics-Pharmacogenomics
- Synthesis Technologies, Production Processes
- Transgenics
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Bioinformatics
- Molecular Diversity
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice